MannKind Corporation (NASDAQ:MNKD) On Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 million weighted average shares outstanding for fiscal year 2012. The number of common shares outstanding at December 31, 2013 was 369,391,972. MannKind Corporation (NASDAQ:MNKD) shares after opening at $5.84 moved to $6.01 on last trade day and at the end of the day closed at $5.89.Price to cash ratio as 28.06. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 4.25%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported its most recent quarterly results February 27. And what came out was not what the Street predicted. The company reported earning -$11 per share in the quarter, missing consensus of $0.02 by $0.13. And the bad news was not just confined to the earnings; revenue also missed the expectation by significant margin, coming in at $6.5 million when Street expected $7 million.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell -3.15% in last trading session and ended the day on $6.31. ARNA return on equity ratio is recorded as -19.10% and its return on assets is -6.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yearly performance is -20.23%.
Even after a resurrected sales approval from the Federal Drug Administration Authority in the USAriad Pharmaceuticals Inc (NASDAQ:ARIA)’s shares are still facing the brunt of the October recall of Iclugis. The BCR-ABL tri-kinase inhibitor for adult patients of chronic or acute myelocytic (or myeloid) leukaemia was re-approved for sale under renewed labeling that cautions of its cardiovascular impacts, so that oncologists refer to it only if need be in extreme cases. That shrunk the market potential and annihilated revenue projections for the coming years. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -0.73% in last trading session and was closed at $8.13, while trading in range of $8.05-$8.40. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date performance is 19.21%.
Idenix Pharmaceuticals, Inc. (IDIX), on Mar. 14 announced that it has filed patent infringement lawsuits against Gilead Sciences, Inc. (GILD) and/or certain of its subsidiaries in each of three countries – France, Germany and the United Kingdom. The lawsuits allege that Gilead infringes Idenix’s recently-granted, co-owned European patent EP 1 523 489 that covers 2′-methyl-2′-fluoro nucleosides for treating the hepatitis C virus. In these lawsuits, Idenix is seeking remedies with respect to Gilead’s marketing and sales of drugs containing sofosbuvir, which Idenix believes infringes its European patent. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is %. On last trading day company shares ended up $75.53. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average is -5.24%. Analysts mean target price for the company is $100.17.